PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth above 1.5x TRVN's 8.42%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.23%
Operating income growth above 1.5x TRVN's 8.42%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
18.34%
Net income growth above 1.5x TRVN's 7.99%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.95%
EPS growth above 1.5x TRVN's 11.28%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
32.95%
Diluted EPS growth above 1.5x TRVN's 14.29%. David Dodd would see if there's a robust moat protecting these shareholder gains.
21.91%
Share count expansion well above TRVN's 3.67%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above TRVN's 7.40%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
46.06%
FCF growth above 1.5x TRVN's 8.88%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while TRVN stands at 21.64%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
85.25%
5Y OCF/share CAGR above 1.5x TRVN's 21.64%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
76.39%
3Y OCF/share CAGR above 1.5x TRVN's 43.01%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-13944.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
85.03%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
64.22%
3Y net income/share CAGR above 1.5x TRVN's 30.28%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
5293.49%
Below 50% of TRVN's 19617.40%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
188.65%
Below 50% of TRVN's 19617.40%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
367.41%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-22.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.